Betsy Nabel and Jeff Brodsky join Accolade Board of Directors New board directors bring expertise in healthcare services, policy, and human resources News provided by Share this article Share this article SEATTLE, June 3, 2021 /PRNewswire/ -- Accolade (Nasdaq: ACCD), the company reinventing healthcare, today announced a series of changes to its board of directors that will bolster the board with significant healthcare and human resources expertise. Jeff Brodsky Dr. Elizabeth Nabel Incoming board member Elizabeth ("Betsy") Nabel, M.D., is executive vice president for strategy at ModeX Therapeutics, developer of innovative immunotherapies for cancer and infectious diseases. Previously, Dr. Nabel served for eleven years as the president of Brigham and Women's Hospital, the second largest teaching hospital of Harvard Medical School and one of the largest hospitals in metro Boston. During her tenure, the hospital became known as one of the safest in the U.S. – including pioneering development of computerized physician order entry (CPOE), now an accepted safety practice in the U.S. and abroad. Earlier in her career, Dr. Nabel directed the National Heart, Lung, and Blood Institute of the National Institutes of Health, overseeing the institute's mission to promote the prevention and treatment of heart, lung, and blood disorders in the United States. Dr. Nabel also serves on the boards of directors of Moderna, a leader in the development of medicines based on messenger RNA (mRNA), as well as Medtronic, one of the world's largest medical device companies.